

Company Overview

Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok[®], CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.

Citius Announces Change To Primary Endpoint In Mino-Lok[®] Phase 3 Study

Sep 4 2019, 6:55 AM EDT

Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

Aug 29 2019, 8:00 AM EDT

Citius Provides Developmental Plans for Mino-Wrap

Jul 30 2019, 8:00 AM EDT

Stock Overview

Symbol	CTXR
Exchange	Nasdaq
Market Cap	20.11m
Last Price	\$0.91
52-Week Range	\$0.85 - \$2.52

09/13/2019 03:58 PM EDT

Investor Relations

Andrew Scott
VP of Investor Relations
T: 908-967-6677 ext. 105

Management Team

Myron Holubiak

President, Chief Executive Officer and Director

Jaime Bartushak

Chief Financial Officer and Principal Financial Officer

Gary F. Talarico

Executive Vice President, Operations

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.